[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eastern Virginia Medical School\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":182},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,69,96,121,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100610231","phase-4-once-daily-vs-twice-daily-insulin-glargine-in-pregestational-diabetes-management-100610231",false,"NCT07224893","Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management","Once-Daily Versus Twice-Daily Insulin Glargine in the Management of Patients With Pregestational Diabetes Requiring Insulin","Inclusion Criteria:\n\n* Patients older than 18 years of age;\n* The patient is fluent in English, physically and mentally able to understand the informed consent, and is willing to participate in this study;\n* Type II diabetes mellitus requiring insulin;\n* The patient is between 24 weeks 0 days and 28 weeks 0 days of gestation at the time of enrollment. Gestational age will be determined by last menstrual period, confirmed with a first trimester ultrasound, per the recommended guidelines by the American College of Obstetricians and Gynecologists.\n* Currently using or willing to use a clinically indicated continuous glucose monitor for glycemic management\n\nExclusion Criteria:\n\n* Known allergy or reaction to insulin glargine, or concurrent medical condition where the use of insulin glargine is contraindicated;\n* Contraindication to CGM use, patient declines CGM use, or CGM not covered by patient's insurance;\n* Known or suspected fetal anomaly or aneuploidy;\n* Prisoners;\n* Ongoing prenatal care outside EVMS or planned delivery outside Sentara Norfolk General Hospital.","FEMALE","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients. Participants in this study will be randomly assigned to one of two groups: a group that takes insulin glargine once a day, and a group that takes it twice. Continuous glucose monitoring will be used to track blood sugar levels. The main question the study aims to answer is: Will using insulin glargine twice a day instead of once lead to a better glucose time in range?",[26,27],"Pregestational Diabetes","Pregnancy",[29],"continuous glucose monitoring","RECRUITING","2026-05-13",{"date":33,"type":34},"2026-05-15","ACTUAL",{"date":36,"type":20},"2026-05-18",{"date":38,"type":20},"2027-12-01",{"name":40,"class":41},"Eastern Virginia Medical School","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100612216","glucose-control-in-type-2-diabetes-in-pregnancy-100612216","NCT07250698","Glucose Control in Type 2 Diabetes in Pregnancy","Postprandial Walks for Glucose Control in Type 2 Diabetes in Pregnancy","Inclusion Criteria:\n\n* Singleton gestation\n* Known diagnosis of Type 2 diabetes OR meets new diagnosis of Type 2 diabetes in the first trimester (up to 13 weeks and 6 days)\n* Age ≥18 and \\\u003C50 years\n* Gestational age \\\u003C32 weeks 0 days gestation\n\nExclusion Criteria:\n\n* Non-English as the primary language\n* Inability to participate in 20 minutes of walking at a time\n* Known or suspected fetal anomaly or aneuploidy\n* Prisoners\n* Management of diabetes outside of study location","50 Years",{"count":52,"type":20},40,[54],"NA","The goal of this clinical trial is to evaluate the effect of physical activity on glucose control in pregnant patients with pregestational Type 2 diabetes. The main question it seeks to answer is \"will physical activity following a meal improve blood sugar control in pregnant women with Type 2 diabetes?\" Researchers will compare the glucose control of two groups: one that walks for 20 minutes after each meal, and one that does not.",[26,57],"Type 2 Diabetes",[59,29],"exercise","NOT_YET_RECRUITING","2025-11-18",{"date":63,"type":34},"2025-11-26",{"date":65,"type":20},"2025-12",{"date":67,"type":20},"2026-12",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100602486","phase-4-lactated-ringers-and-dextrose-5-vs-only-lactated-ringers-in-labor-100602486","NCT07124130","Lactated Ringer's and Dextrose 5% vs Only Lactated Ringer's in Labor","Parenteral Lactated Ringer's Plus Dextrose 5% vs Lactated Ringer's in Labor: A Randomized Control Trial on Maternal and Neonatal Outcomes","Inclusion Criteria:\n\n* Nulliparous women\n* Age 18 years or older and able to provide informed consent\n* Singleton pregnancy at term\n* Induction of labor\n* Cephalic presentation\n* Unfavorable cervix (Bishop score ≤ 6)\n\nExclusion Criteria:\n\n* Age under 18 years\n* Involuntarily confined or detained\n* Considered as having diminished decision-making capacity\n* Spontaneous labor (cervical exam between 5-6 cm) with or without ruptured membraned\n* Favorable cervix (Bishop score \\>6)\n* Diabetes mellitus (both gestational and pre-gestational)\n* Structural renal disease\n* Acute or chronic kidney disease resulting in abnormal creatinine or proteinuria\n* Evidence of chorioamnionitis or non-reassuring fetal testing at the time of enrollment\n* Pyrexia (\\>38.0 degrees Celsius)\n* Stillbirth\n* Planned cesarean delivery\n* Women presenting with emergent circumstances for labor induction",{"count":77,"type":20},158,[23],"The goal of this clinical trial is to determine which of two types of standard intravenous (IV) fluids (a combination of 5% dextrose and Lactated Ringers solution and Lactated Ringers solution alone) has a better influence on labor when inducing labor in pregnant women. The main questions it aims to answer are:\n\n1. Does the use of 5% dextrose and Lactated Ringers lead to a shorter labor than the use of just Lactated Ringers?\n2. Does the use of 5% dextrose and Lactated Ringers increase the risk of neonatal hypoglycemia when compared to Lactated Ringers? Participants in this trial will be randomly assigned to one of two groups: a group that receives a solution of 5% dextrose and Lactated Ringers, and a group that receives Lactated Ringers alone. Researchers will compare the outcomes of the two groups to see which IV fluid is more effective.",[81],"Induced Labor",[83,84,85,86],"Induced labor","5% dextrose","Lactated Ringers","duration of labor","2025-08-18",{"date":89,"type":34},"2025-08-22",{"date":91,"type":20},"2025-09",{"date":93,"type":20},"2026-03",{"name":40,"class":41},2,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":42},"100602122","phase-4-oxytocinfoley-vs-oxytocin-for-induction-in-patients-with-pprom-100602122","NCT07119398","Oxytocin\u002FFoley vs. Oxytocin for Induction in Patients With PPROM","Combination Oxytocin\u002FFoley Versus Oxytocin Alone for Induction of Labor in Patients With Preterm Prelabor Rupture of Membranes","Inclusion Criteria:\n\n* Patients 18-50 years of age;\n* The patient is fluent in English, physically and mentally able to understand the informed consent, and is willing to participate in this study;\n* PPROM;\n* Cervical dilation \\\u003C\u002F= 2cm\n* Fetal cephalic presentation;\n* The patient is between 34 weeks 0 days and 36 weeks 6 days of gestation at the time of enrollment. Gestational age will be determined by last menstrual period, confirmed with a first trimester ultrasound, per the recommended guidelines by the American College of Obstetricians and Gynecologists.\n\nExclusion Criteria:\n\n* Spontaneous labor\n* Known allergy to latex;\n* Cervical dilation \\>2cm;\n* Chorioamnionitis;\n* Contraindications to induction of labor or use of Foley for cervical ripening\n* HIV\n* Known or suspected fetal anomaly or aneuploidy;\n* Prisoners.",{"count":104,"type":20},80,[23],"Data on the optimal mode of labor induction after preterm prelabor rupture of membranes (PPROM) is lacking. Studies have shown no difference between oxytocin and misoprostol use for labor induction in this cohort (1). The preponderance of evidence from term pregnancies suggests that Foley catheter coupled with oxytocin is better than oxytocin alone, with a higher rate of delivery within 24 hours when a Foley catheter followed by oxytocin is compared to oxytocin alone. However, the use of a Foley catheter has not been evaluated in prospective studies on patients with PPROM.",[108],"Preterm PROM (Pregnancy)",[110,111,112],"Induction","PPROM","Preterm prelabor rupture of membranes","2025-08-05",{"date":115,"type":34},"2025-08-13",{"date":117,"type":34},"2025-07-14",{"date":119,"type":20},"2026-12-30",{"name":40,"class":41},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":42},"100582788","effect-of-fiber-supplementation-on-the-need-for-medication-with-gestational-diabetes-100582788","NCT06867861","Effect of Fiber Supplementation on the Need for Medication With Gestational Diabetes","Effect of Fiber Supplementation on the Need for Medication With Gestational Diabetes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Singleton gestation\n* Known or new diagnosis of gestational diabetes without reason for medication\n* Age \\>=18 to \\\u003C=50\n\nExclusion Criteria:\n\n* \\- Non-English as primary language.\n* Known or suspected fetal anomaly or aneuploidy.\n* Known lower bowel disorder\n* Known phenylketonuria\n* Prisoners.\n* Management of diabetes outside of Eastern Virginia Medical School Maternal Fetal Medicine.",{"count":129,"type":20},110,[54],"The hypotheses to be tested are 1) Fiber supplementation will decrease the need for medication in patients with gestational diabetes, and 2) Fiber supplementation will decrease adverse maternal and neonatal outcomes in these patients. In this study, the investigators will conduct a randomized controlled trial to limit bias in evaluating these hypotheses.",[133],"Gestational Diabetes Mellitus (GDM)",[135,136,137],"Gestational Diabetes Mellitus","Fiber","GDM","2025-03-05",{"date":140,"type":34},"2025-03-10",{"date":142,"type":34},"2025-02-24",{"date":144,"type":20},"2026-08-26",{"name":40,"class":41},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":152,"minAge":50,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":42},"100395975","phase-2-effects-of-thc-free-cbd-oil-on-agitation-in-patients-with-alzheimers-disease-100395975","NCT04436081","Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease","Inclusion Criteria:\n\n* Males\u002Ffemales over 50 years old.\n* Have a diagnosis of dementia due to AD or mixed AD with another type of dementia.\n* A Mini-Mental State Exam score (MMSE) between 4 and 28 inclusive.\n* Presence of agitation with a Neuropsychiatric Inventory (NPI)-agitation\u002Faggression subscore \\> 3.\n* Participants and their informal caregivers must be fluent in English (includes reading, writing, and speech) and able to give informed consent.\n* For patients treated with cognitive-enhancing medications (cholinesterase inhibitors (ChEI) and\u002For memantine), the dosage must be stable for at least 1 month (30 days). If the ChEI and\u002For memantine has been discontinued, patients may enroll after 15 days.\n* Eligible caregivers must either live with the participant or have a minimum of 4 hours of daily contact with them.\n\nExclusion Criteria:\n\n* Diagnosis of non-AD or non-mixed dementias.\n* Very mild dementia or advanced dementia (MMSE: greater than 28 or less than 4).\n* NPI-agitation-aggression score \\\u003C 3.\n* Having a serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease which might confound assessment of safety outcomes as determined by the study physician.\n* Presence or history of other serious psychiatric disorders or neurological conditions (e.g. psychotic disorders, bipolar disorder or schizophrenia).\n* Current abuse of\u002Fdependence on marijuana, current drug abuse, current alcohol abuse.\n* Having seizure disorders.\n* Pregnant or breastfeeding\n* Indication of baseline delirium as determined by the Confusion Assessment Method (CAM).\n* Current use of lithium.\n* Inability to swallow CBD oil softgels.\n* Changes in dosage of anti-depressives within 4 weeks before randomization and during the study.\n* Changes in dosage of antipsychotics or benzodiazepines within 1 week prior to randomization and during the study.\n* Contraindications to CBD oil (history of hypersensitivity to any cannabinoid).\n* Frequent falling due to orthostatic hypotension.\n* Use of tricyclic antidepressants (TCA), fluoxetine, and\u002For carbamazepine. -Patients who reside in nursing homes.","ALL","90 Years",{"count":52,"type":20},[156],"PHASE2","This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.",[159,160,161],"Alzheimer Disease","Dementia","Major Neurocognitive Disorder With Aggressive Behavior",[163,164,165,166,167,168,169,170,171,172,173],"Agitation","Aggression","Neuropsychiatric symptoms","CBD Oil","Cannabinoids","Caregiver burden","Sleep quality","Behavioral and Psychological Symptoms of Dementia","Neurocognitive disorders","Psychomotor agitation","Cannabidiols","2023-02-15",{"date":176,"type":34},"2023-02-16",{"date":178,"type":34},"2021-02-26",{"date":180,"type":20},"2024-03",{"name":40,"class":41},""]